Patent ID: 8383585

Claim:
A method of treating cardiodiabetes in a normoglycemic subject comprising: (a) measuring the concentration of a biomarker panel in a sample from the subject, the biomarker panel consisting of adiponectin, high sensitivity C-reactive protein (hsCRP) and intact proinsulin; and (b) determining a risk level associated with each biomarker, wherein an adiponectin concentration of >10 mg/L, 7-10 mg/L and <7 mg/L indicates a low, medium and high risk level, respectively, for adiponectin; an hsCRP concentration of 0-1 mg/L, >1-3 mg/L and >3-10 mg/L indicates a low, medium and high risk level, respectively, for hsCRP; and an intact proinsulin concentration of ≦11 pmol/L and >11 pmol/L indicates a low and high risk level, respectively, for intact proinsulin; (c) comparing the concentrations to each of the risk levels; and (d) effecting a therapy with respect to the subject, wherein in the therapy is based on a combination of the risk levels.